Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us


Session 93   Poster Abstracts
Interplay between STI's and Drug Resistance
Tuesday, 1:30 - 3:30 pm
Poster Hall
663Changes in T-cell Activation and CD4 Counts during Partial Treatment Interruption of Protease Inhibitor Therapy
P W Hunt*1, J N Martin1, E Sinclair1, B Bredt1, R Ho1, G Tsao1, T B Neilands1, C Petropolous2, R M Grant3, and S G Deeks1
1Univ. of California, San Francisco, USA; 2ViroLogic Inc., South San Francisco, CA, USA; and 3Gladstone Inst. of Virology and Immunology, San Francisco, CA, USA
664Purging of Monocytes Improves the Virological and Immunological Response to HAART Reintroduction after Structured Treatment Interruptions in HIV-infected Multiple Drug-resistant Patients
H Hasson1, P Biswas1, B Mantelli1, S Nozza1, A Vecchi1, M Malnati2, S Saniabadi3, A Lazzarin1, and A Beretta*1
1Infectious Diseases Clinic. S.Raffaele Hosp.. Milan.Italy; 2DIBIT, S. Raffaele Sci. Inst., Milan, Italy; and 3Japan ImmunoRes. Inst., Takasaki, Japan
665
Changes in HIV-resistance Patterns during Structured Treatment Interruption: CPCRA 064
J Lawrence1, K Huppler Hullsiek*2, D Abrams1, J Baxter3, and CPCRA 064
1Univ. of California, San Francisco, USA; 2Univ. of Minnesota, Minneapolis, USA; and 3Cooper Hosp./RWJ Med. Sch.
666
Comparison of the Dynamics of Resistance-associated Mutations to NRTI, NNRTI, and PI after Cessation of Antiretroviral Combination Therapy
M Wirden*, B Amellal, C Delaugerre, A G Marcelin, N Ktorza, H Ait-Mohand, L Schneider, C Katlama, and V Calvez
Pitié-Salpêtrière Hosp., Paris, France
667Viral Populations with Distinct Drug-resistant Genotypes Shift during Repeated Structured Treatment Interruptions
G Ellis*1, W Borkowsky2, R Yogev3, B Ank4, P Muresan5, T Fenton5, B Heckman6, E McFarland7, E Capparelli8, J Moye9, S Jankelevich9, L Frenkel1, and the PACTG
1Univ. of Washington, Seattle, USA; 2New York Univ. Sch. of Med., NY, USA; 3Children's Mem. Hosp., Chicago, IL, USA; 4Univ. of California, Los Angeles, Sch. of Med., USA; 5Frontier Sci. and Technology Res. Fndn.-Harvard Sch. of Publ. Hlth., Boston, MA, USA; 6Frontier Sci. and Technology Res. Fndn.-Data Management Ctr., Amherst, NY, USA; 7Univ. of Colorado Hlth. Sci. Ctr., Denver, USA; 8Univ. of California, San Diego, USA; and 9NICHD, NIH, DHHS, Bethesda, MD, USA
668Risk of Developing Selected de novo Resistance Mutations during Structured Therapy Interruption in Chronic HIV-1 Infection.
M Arnedo-Valero*, F Garcia, C Gil, P Castro, J L Blanco, J M Miro, T Pumarola, and J M Gatell
IDIBAPS, Hosp. Clin. Barcelona, Univ. of Barcelona, Spain